1.
Characteristics of eligible patients (N=79)
| Variables | n (%) | P | n (%) | P | ||
| Alive | Death | Non-progression | Progression | |||
| ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell transplantation; DLBCL, diffuse large B cell lymphoma; NKTCL, natural killer/T-cell lymphoma. | ||||||
| Gender | 0.553 | 0.340 | ||||
| Male | 41 (63.1) | 10 (71.4) | 37 (61.7) | 14 (73.7) | ||
| Female | 24 (36.9) | 4 (28.6) | 23 (38.3) | 5 (26.3) | ||
| Age (year) [mean (range)] | 34.72 (11.2–60.7) | 43.29 (19.7–61.8) | 34.63 (11.2–60.7) | 41.30 (17.5–61.8) | 0.084 | |
| B systoms | 0.928 | 0.570 | ||||
| Negative | 38 (58.5) | 8 (57.1) | 36 (60.0) | 10 (52.6) | ||
| Positive | 27 (41.5) | 6 (42.9) | 24 (40.0) | 9 (47.4) | ||
| Stage | 0.038 | 0.012 | ||||
| I–II | 49 (75.4) | 14 (100) | 44 (73.3) | 0 (0) | ||
| III–IV | 16 (24.6) | 0 (0) | 16 (26.7) | 19 (100) | ||
| ECOG | 0.083 | 0.213 | ||||
| 0–1 | 63 (96.9) | 12 (85.7) | 58 (96.7) | 17 (89.5) | ||
| ≥2 | 2 (3.1) | 2 (14.3) | 2 (3.3) | 2 (10.5) | ||
| Extranodal sites | 0.665 | 0.260 | ||||
| 0–1 | 32 (49.2) | 6 (42.9) | 31 (51.7) | 7 (36.8) | ||
| ≥2 | 33 (50.8) | 8 (57.1) | 29 (48.3) | 12 (63.2) | ||
| Bulky disease | 0.365 | 0.088 | ||||
| <5 cm | 43 (66.2) | 11 (78.6) | 38 (63.3) | 16 (84.2) | ||
| >5 cm | 22 (33.8) | 3 (21.4) | 22 (36.7) | 3 (15.8) | ||
| No. of chemotherapy regimens before ASCT | 0.004 | <0.001 | ||||
| <2 | 45 (69.2) | 4 (28.6) | 44 (73.3) | 5 (26.3) | ||
| ≥2 | 20 (30.8) | 10 (71.4) | 16 (26.7) | 14 (73.7) | ||
| Diagnosis | 0.368 | 0.412 | ||||
| DLBCL | 35 (53.8) | 7 (50.0) | 33 (55.0) | 9 (47.4) | ||
| NKTCL | 9 (13.8) | 4 (28.6) | 8 (13.3) | 5 (26.3) | ||
| Others | 21 (32.3) | 3 (21.4) | 19 (31.7) | 5 (26.3) | ||